Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBOOT ABLY in Advanced B-cell Lymphoma
NCT01859819Phase 2Completed
- Sponsor
- New York Medical College
- Start
- Jan 2013
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of liposomal cytarabine, rituximab in B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), sponsored by New York Medical College. Started Jan 2013; status: completed.
02
Drugs
liposomal cytarabinerituximab
03
Conditions
B cell lymphomadiffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT01859819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01859819.